GO:0038083 peptidyl-tyrosine autophosphorylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038083 (peptidyl-tyrosine autophosphorylation) describes the phosphorylation by a protein of one or more of its own tyrosine residues, or a tyrosine residue on an identical protein.
• This process is a hallmark of receptor tyrosine kinase (RTK) activation and is frequently studied in cancer, where autophosphorylation drives oncogenic signaling.
• Dysregulated autophosphorylation is implicated in breast cancer recurrence, acute lymphoblastic leukemia, cervical cancer radiotherapy resistance, esophageal squamous cell carcinoma, nephrotic syndrome, and uveal melanoma liver metastasis.
• Key genes involved include PTCH1, LINC00152, and TIMP1, which have been linked to autophosphorylation-related pathways in various cancers.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting the causal role of autophosphorylation in disease.
• Understanding peptidyl-tyrosine autophosphorylation provides insights into signal transduction and offers therapeutic targets for multiple malignancies.
Description
Peptidyl-tyrosine autophosphorylation (GO:0038083) is a biological process in which a protein phosphorylates its own tyrosine residues or those of an identical protein molecule. This self-modification is a critical mechanism for regulating protein function, particularly in receptor tyrosine kinases (RTKs), where autophosphorylation serves as a switch for downstream signaling. The process is essential for cellular responses to growth factors, hormones, and other extracellular cues, and its dysregulation is a common feature in human diseases, especially cancer. Researchers study this term to understand how aberrant autophosphorylation contributes to tumorigenesis, metastasis, and therapy resistance, and to identify potential therapeutic targets.
peptidyl-tyrosine autophosphorylation At A Glance
| GO ID | GO:0038083 |
|---|---|
| GO term | peptidyl-tyrosine autophosphorylation |
| Ontology | biological_process |
| Synonym | receptor tyrosine kinase autophosphorylation, RTK autophosphorylation, tyrosine autophosphorylation |
| Major function | Self-phosphorylation of tyrosine residues to regulate protein activity and signaling |
| Definition | The phosphorylation by a protein of one or more of its own tyrosine amino acid residues, or a tyrosine residue on an identical protein |
| Related diseases | Breast cancer, acute lymphoblastic leukemia, cervical cancer, esophageal squamous cell carcinoma, nephrotic syndrome, uveal melanoma |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, bioinformatics |
What Is GO:0038083?
According to the Gene Ontology, peptidyl-tyrosine autophosphorylation is defined as the phosphorylation by a protein of one or more of its own tyrosine amino acid residues, or a tyrosine residue on an identical protein. This process is synonymous with receptor tyrosine kinase autophosphorylation, RTK autophosphorylation, and tyrosine autophosphorylation. It represents a specific type of post-translational modification where the kinase domain of a protein catalyzes the transfer of a phosphate group from ATP to its own tyrosine residues, leading to conformational changes and activation of signaling pathways.
Why Is peptidyl-tyrosine autophosphorylation Important in Cell Biology?
Peptidyl-tyrosine autophosphorylation is a fundamental regulatory mechanism in cell signaling, controlling processes such as proliferation, differentiation, survival, and migration. Its dysregulation is causally linked to numerous human diseases, including various cancers and metabolic disorders. For example, mutations in PTCH1 that affect autophosphorylation are associated with breast cancer recurrence, and LINC00152 has been identified as a biomarker in acute lymphoblastic leukemia. Understanding this process at the molecular level is therefore crucial for developing targeted therapies and diagnostic tools.
• Drives oncogenic signaling in breast cancer, where PTCH1 mutations predict recurrence.
• Serves as a biomarker for early relapse and mortality in acute lymphoblastic leukemia via LINC00152.
• Contributes to radiotherapy resistance in cervical cancer.
• Involved in the pathogenesis of esophageal squamous cell carcinoma through methylated and differentially expressed genes.
• Plays a role in nephrotic syndrome, as revealed by metabolomic and bioinformatic analyses of Danggui-Shaoyao-San.
• Associated with liver metastasis of uveal melanoma, with TIMP1 as a key gene.
• Provides targets for CRISPR-based knockout and point mutation studies to dissect causal roles.
• Enables the development of small molecule inhibitors that block autophosphorylation for therapeutic benefit.
• Facilitates the identification of novel biomarkers through transcriptome and bioinformatics analyses.
• Underpins personalized medicine approaches by linking genetic alterations to disease outcomes.
What Happens During peptidyl-tyrosine autophosphorylation?
Ligand-Induced Dimerization and Activation
In simple terms: When a signaling molecule binds to a receptor, two receptors pair up and turn each other on.
In receptor tyrosine kinases (RTKs), autophosphorylation typically begins with ligand binding, which induces receptor dimerization. This brings the intracellular kinase domains into close proximity, allowing them to phosphorylate each other on tyrosine residues. This trans-autophosphorylation stabilizes the active conformation and creates docking sites for downstream signaling proteins. Dysregulation of this step is observed in cancers such as breast cancer, where PTCH1 mutations affect signaling.
Catalytic Transfer of Phosphate Groups
In simple terms: The kinase part of the protein attaches a phosphate tag to its own tyrosine building blocks.
The kinase domain catalyzes the transfer of a gamma-phosphate from ATP to the hydroxyl group of a tyrosine residue. This autophosphorylation can occur in cis (within the same molecule) or in trans (between two identical molecules). The reaction is tightly regulated and requires magnesium or manganese ions as cofactors. In acute lymphoblastic leukemia, aberrant autophosphorylation of signaling proteins contributes to leukemogenesis, as highlighted by transcriptome analyses identifying LINC00152.
Conformational Changes and Signal Propagation
In simple terms: Adding phosphate tags changes the protein's shape, letting it interact with other proteins to pass on the signal.
Phosphorylated tyrosine residues serve as binding sites for Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains of adaptor proteins. This recruitment initiates downstream signaling cascades, such as the MAPK and PI3K-AKT pathways, which control cell proliferation and survival. In cervical cancer, radiotherapy resistance has been linked to altered expression of genes involved in such signaling, as identified by RNA sequencing.
Feedback Regulation and Termination
In simple terms: The signal is eventually shut off by enzymes that remove the phosphate tags.
Protein tyrosine phosphatases (PTPs) counteract autophosphorylation by dephosphorylating tyrosine residues, thereby terminating signaling. This balance is critical for normal cellular homeostasis, and its disruption can lead to disease. For instance, in esophageal squamous cell carcinoma, differential methylation of genes related to tyrosine phosphorylation may contribute to tumorigenesis. Similarly, in nephrotic syndrome, metabolomic and bioinformatic analyses suggest that Danggui-Shaoyao-San may modulate autophosphorylation-related pathways.
Key Genes Involved in GO:0038083 peptidyl-tyrosine autophosphorylation
The following genes and proteins are directly implicated in peptidyl-tyrosine autophosphorylation or its regulatory networks, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTCH1 | Receptor for Hedgehog signaling; mutations affect autophosphorylation | Predicts breast cancer recurrence |
| LINC00152 | Long non-coding RNA; regulates signaling pathways | Biomarker for early relapse and mortality in acute lymphoblastic leukemia |
| TIMP1 | Inhibitor of matrix metalloproteinases; involved in cell signaling | Associated with liver metastases of uveal melanoma |
| EGFR | Receptor tyrosine kinase; autophosphorylation drives proliferation | Target in various cancers; studied via CRISPR models |
| SRC | Non-receptor tyrosine kinase; autophosphorylation regulates activity | Oncogene in multiple cancers |
| ABL1 | Tyrosine kinase; autophosphorylation in leukemia | Target of imatinib; studied in CML |
| JAK2 | Janus kinase; autophosphorylation in cytokine signaling | Mutations in myeloproliferative neoplasms |
| STAT3 | Transcription factor; phosphorylated by JAK2 | Constitutively active in many cancers |
| PIK3CA | Catalytic subunit of PI3K; involved in autophosphorylation-dependent pathways | Frequently mutated in breast cancer |
| AKT1 | Serine/threonine kinase; activated downstream of RTKs | Oncogene in breast, cervical cancers |
| MAPK1 | Extracellular signal-regulated kinase 2; downstream of RTKs | Regulates proliferation; target in melanoma |
| PTEN | Phosphatase; negatively regulates PI3K-AKT signaling | Tumor suppressor; mutated in many cancers |
| PTPN11 | Protein tyrosine phosphatase; regulates autophosphorylation | Mutations in Noonan syndrome and leukemia |
| GRB2 | Adaptor protein; binds phosphotyrosines | Links RTKs to RAS-MAPK pathway |
| SHC1 | Adaptor protein; binds autophosphorylated RTKs | Activates MAPK pathway |
| CBL | E3 ubiquitin ligase; regulates RTK degradation | Modulates autophosphorylation-induced signaling |
| VAV1 | Guanine nucleotide exchange factor; activated by tyrosine phosphorylation | Involved in hematological malignancies |
| PLCG1 | Phospholipase C gamma 1; binds autophosphorylated RTKs | Mediates calcium signaling |
How Is peptidyl-tyrosine autophosphorylation Regulated?
Peptidyl-tyrosine autophosphorylation is regulated by multiple mechanisms, including ligand availability, receptor dimerization, and the opposing action of protein tyrosine phosphatases (PTPs). For example, PTPN11 (SHP-2) can dephosphorylate RTKs and modulate downstream signaling. Additionally, feedback loops involving downstream kinases such as ERK can phosphorylate RTKs at inhibitory sites, reducing autophosphorylation. In disease contexts, dysregulation of these regulatory circuits contributes to oncogenesis, as seen in breast cancer with PTCH1 mutations and in acute lymphoblastic leukemia with LINC00152 dysregulation. Understanding these regulatory mechanisms is essential for designing targeted therapies.
peptidyl-tyrosine autophosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTCH1 | Breast cancer recurrence | Knockout or point mutation in breast cancer cell lines |
| LINC00152 | Acute lymphoblastic leukemia relapse | Overexpression or knockout in ALL cell lines |
| TIMP1 | Uveal melanoma liver metastasis | Knockdown or knockout in uveal melanoma cells |
| EGFR | Various cancers | Point mutation (e.g., L858R) knock-in in lung cancer cells |
| JAK2 | Myeloproliferative neoplasms | V617F knock-in in hematopoietic stem cells |
Breast Cancer Recurrence and PTCH1
Mutations in the PTCH1 gene, which encodes a receptor for Hedgehog signaling, have been shown to predict recurrence in breast cancer. PTCH1 autophosphorylation and downstream signaling are critical for tumor progression, and its mutation status may serve as a prognostic biomarker. This highlights the importance of peptidyl-tyrosine autophosphorylation in breast cancer biology.
Acute Lymphoblastic Leukemia and LINC00152
Transcriptome analysis identified LINC00152 as a biomarker of early relapse and mortality in acute lymphoblastic leukemia (ALL). LINC00152 may regulate signaling pathways involving tyrosine autophosphorylation, contributing to leukemogenesis and therapy resistance. Targeting this pathway could improve outcomes in ALL patients.
Cervical Cancer Radiotherapy Resistance
RNA sequencing data identified biomarkers for cervical cancer radiotherapy resistance, including genes involved in tyrosine kinase signaling. Autophosphorylation of RTKs can promote survival pathways that confer resistance to radiation, making it a potential therapeutic target.
Uveal Melanoma Liver Metastasis and TIMP1
Weighted gene co-expression network analysis identified TIMP1 as a key gene associated with liver metastases of uveal melanoma. TIMP1 is involved in cell signaling and may influence autophosphorylation-dependent pathways that drive metastasis. This underscores the role of tyrosine autophosphorylation in cancer dissemination.
From peptidyl-tyrosine autophosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTCH1 mutation affect autophosphorylation and breast cancer recurrence? | Knockout or point mutation of PTCH1 in breast cancer cell lines |
| What is the role of LINC00152 in ALL relapse? | Overexpression or knockout of LINC00152 in ALL cell lines |
| How does TIMP1 contribute to uveal melanoma metastasis? | Knockdown or knockout of TIMP1 in uveal melanoma cells |
| Does EGFR autophosphorylation drive cervical cancer radioresistance? | Point mutation (e.g., T790M) knock-in in cervical cancer cells |
| Can JAK2 V617F be targeted to reduce autophosphorylation? | Knock-in of JAK2 V617F in hematopoietic cells |
| What is the effect of PTPN11 mutations on autophosphorylation? | Point mutation knock-in in leukemia cell lines |
How to Study the peptidyl-tyrosine autophosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on autophosphorylation | Identify essential kinases |
| Phosphoproteomics | Global tyrosine phosphorylation levels | Quantify autophosphorylation changes |
| RNA-seq | Transcriptional changes | Discover biomarkers like LINC00152 |
| WGCNA | Gene co-expression networks | Identify key genes like TIMP1 |
| Metabolomics | Metabolite profiles | Link metabolism to autophosphorylation |
| Western blot | Specific protein phosphorylation | Validate autophosphorylation of targets |
| Immunoprecipitation | Protein-protein interactions | Study autophosphorylation-dependent complexes |
| Flow cytometry | Cell signaling and surface markers | Assess pathway activation |
CRISPR-Based Genetic Screens
CRISPR knockout and activation screens can identify genes that regulate peptidyl-tyrosine autophosphorylation. For example, a genome-wide knockout screen in breast cancer cells could reveal modifiers of PTCH1 signaling. Similarly, screens in ALL cells may uncover regulators of LINC00152.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of tyrosine autophosphorylation events. This method can quantify changes in phosphorylation upon genetic perturbations, such as PTCH1 mutation or TIMP1 knockdown, providing insights into signaling networks.
Transcriptome Analysis
RNA sequencing (RNA-seq) is used to identify differentially expressed genes and pathways associated with autophosphorylation. Studies in cervical cancer and esophageal squamous cell carcinoma have utilized RNA-seq to uncover biomarkers and therapeutic targets.
Bioinformatics and Network Analysis
Weighted gene co-expression network analysis (WGCNA) and other bioinformatic approaches integrate multi-omics data to identify key genes and pathways. For instance, WGCNA identified TIMP1 in uveal melanoma, and metabolomic-bioinformatic analyses revealed mechanisms in nephrotic syndrome.
How CRISPR Can Be Used to Study GO:0038083 peptidyl-tyrosine autophosphorylation
Knockout
CRISPR knockout is used to completely abolish the expression of genes involved in peptidyl-tyrosine autophosphorylation, such as PTCH1 or TIMP1, to study their loss-of-function phenotypes. For example, knocking out PTCH1 in breast cancer cells can reveal its role in recurrence, while TIMP1 knockout in uveal melanoma cells can assess metastasis potential.
Point Mutation
Point mutation knock-in via CRISPR allows the introduction of specific amino acid substitutions that mimic or disrupt autophosphorylation sites. For instance, mutating tyrosine residues in EGFR to phenylalanine can prevent autophosphorylation and block downstream signaling, providing insights into cervical cancer radioresistance.
Knock-in
Knock-in of reporter tags or disease-associated mutations (e.g., JAK2 V617F) enables real-time monitoring of autophosphorylation and its effects on cellular behavior. This approach is valuable for studying leukemogenesis and testing targeted therapies.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can drive high-level expression of genes like LINC00152 to investigate their role in autophosphorylation and disease. Overexpression of LINC00152 in ALL cells may recapitulate relapse phenotypes.
How EDITGENE Supports peptidyl-tyrosine autophosphorylation Research
Researchers studying peptidyl-tyrosine autophosphorylation-related genes often need to determine whether a candidate gene is causally involved in disease or signaling. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for peptidyl-tyrosine autophosphorylation research.
Frequently Asked Questions About peptidyl-tyrosine autophosphorylation
What is peptidyl-tyrosine autophosphorylation?
Peptidyl-tyrosine autophosphorylation (GO:0038083) is the process by which a protein phosphorylates its own tyrosine residues or those of an identical protein, often leading to activation of signaling pathways.
What genes are involved in peptidyl-tyrosine autophosphorylation?
Key genes include PTCH1, LINC00152, TIMP1, EGFR, SRC, ABL1, JAK2, and many others that encode kinases or regulators of this process.
How is peptidyl-tyrosine autophosphorylation studied?
It is studied using CRISPR knockout, point mutation, knock-in, overexpression models, as well as phosphoproteomics, RNA-seq, and bioinformatics analyses.
Why is peptidyl-tyrosine autophosphorylation important in cancer?
Dysregulated autophosphorylation drives oncogenic signaling, contributing to breast cancer recurrence, leukemia, cervical cancer resistance, and melanoma metastasis.
What diseases are associated with peptidyl-tyrosine autophosphorylation?
It is associated with breast cancer, acute lymphoblastic leukemia, cervical cancer, esophageal squamous cell carcinoma, nephrotic syndrome, and uveal melanoma.
Can CRISPR be used to study peptidyl-tyrosine autophosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect the causal roles of genes in this process.
What is the role of PTCH1 in autophosphorylation?
PTCH1 mutations affect autophosphorylation-dependent signaling and predict breast cancer recurrence.
How does LINC00152 relate to autophosphorylation?
LINC00152 is a biomarker for early relapse in acute lymphoblastic leukemia and may regulate autophosphorylation pathways.
What methods identify biomarkers for autophosphorylation-related diseases?
RNA sequencing, WGCNA, metabolomics, and phosphoproteomics are commonly used to identify biomarkers.
What services does EDITGENE offer for autophosphorylation research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study peptidyl-tyrosine autophosphorylation.
Conclusion
Peptidyl-tyrosine autophosphorylation (GO:0038083) is a central regulatory mechanism in cell signaling, with profound implications for human health and disease. Dysregulation of this process is implicated in a wide range of cancers and other disorders, as evidenced by studies on PTCH1, LINC00152, TIMP1, and other genes. Advances in CRISPR-based models and bioinformatics are accelerating our understanding of these pathways and enabling the development of targeted therapies. Continued research into peptidyl-tyrosine autophosphorylation will undoubtedly yield new insights and therapeutic opportunities.
References
- 1. Wang CY et al.. 2019. Mutation of the PTCH1 gene predicts recurrence of breast cancer.. Sci Rep 9(1):16359 PMID: 31704974
- 2. Bárcenas-López DA et al.. 2020. Transcriptome Analysis Identifies LINC00152 as a Biomarker of Early Relapse and Mortality in Acute Lymphoblastic Leukemia.. Genes (Basel) 11(3) PMID: 32183133
- 3. Feng Y et al.. 2021. Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data.. Front Cell Dev Biol 9:724172 PMID: 34414195
- 4. Peng H et al.. 2019. Comprehensive bioinformation analysis of methylated and differentially expressed genes in esophageal squamous cell carcinoma.. Mol Omics 15(1):88-100 PMID: 30706927
- 5. Wang Y et al.. 2020. Evaluation of the mechanism of Danggui-Shaoyao-San in regulating the metabolome of nephrotic syndrome based on urinary metabonomics and bioinformatics approaches.. J Ethnopharmacol 261:113020 PMID: 32592886
- 6. Wang P et al.. 2020. Identifying a Potential Key Gene, TIMP1, Associated with Liver Metastases of Uveal Melanoma by Weight Gene Co-Expression Network Analysis.. Onco Targets Ther 13:11923-11934 PMID: 33239893
